Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study

• Main Authors: Sophie Stukas (Author), George Goshua (Author), Angus Kinkade (Author), Rebecca Grey (Author), Gregory Mah (Author), Catherine M. Biggs (Author), Shahin Jamal (Author), Sonny Thiara (Author), Tim T.Y. Lau (Author), Jolanta Piszczek (Author), Nilu Partovi (Author), David D Sweet (Author), Agnes Y.Y. Lee (Author), Cheryl L. Wellington (Author), Mypinder S. Sekhon (Author), Luke Y.C. Chen (Author)
• Format: Book
• Published: Elsevier, 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Interleukin-6 inhibitors reduce mortality in severe COVID-19. British Columbia began using tocilizumab 8 mg/kg (maximum 800 mg) in January 2021 in critically ill patients with COVID-19, but due to drug shortages, decreased dosing to 400 mg IV fixed dose in April 2021. The aims o...